Mobile Health and Wearable Devices for Diabetes Complication Management
Condition(s) studied
Investigational drug(s) / intervention(s)
Device: No specific devices: Routine doctor-patient interaction.
Device: CGM,CGM management platform: Wearable monitoring + CGM management platform-assisted administration
Device: "Professor Tang" WeChat Mini-program: Mini-program-assisted health management
Device: CGM, Smart Bracelet, "Professor Tang" WeChat Mini-program: Wearable monitoring + mini-program integrated management
Study summary
The value of intelligent lifestyle intervention for T2D and its complications has been initially explored, but evidence-based support for the effectiveness of related AI risk prediction models and intervention models remains to be confirmed. The primary objective of this study is to verify the effectiveness of an AI model for predicting the risk of T2D complications based on phenotype, laboratory indicators and wearable device indicators, and to explore the effect and applicability of an intelligent lifestyle intervention model combining wearable devices and smartphones in preventing T2D complications.
Eligibility
Primary outcome measure(s)
- HbA1c — Baseline, 1 year
Between-group differences in HbA1c change (from Central Lab)
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Second Xiangya Hospital of Central South University | Changsha | China | Recruiting |
More Second Xiangya Hospital of Central South University trials in China
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07129148 on ClinicalTrials.gov ↗ ← All trials in China